Why McKesson (MCK) is a Top Growth Stock for the Long-Term

McKesson is projected to grow current-year earnings 14.1% year over year, supported by specialty pharmaceuticals, oncology services and GLP-1 drugs; FY25 GLP-1 revenue reached nearly $41 billion. Seven analysts raised FY2027 estimates over the past 60 days, lifting the consensus EPS forecast by $0.36 to $44.64, while McKesson's average earnings surprise is 4.3%. Zacks rates MCK Hold, but assigns A grades for Growth and VGM, presenting a constructive long-term growth case rather than a material near-term catalyst.

Analysis

The investable issue is not distributor revenue growth but incremental gross-profit capture and working-capital intensity. GLP-1 volume is economically attractive only if it increases specialty-services attach rates, manufacturer fees, and customer retention; pass-through drug sales alone carry thin margins and can consume cash as inventory and receivables scale. MCK's differentiated oncology/RxTS assets make it better positioned than broadline peer Cencora (COR) to monetize patient-access and manufacturer-services complexity, while Cardinal Health (CAH) remains the cleaner comparator for any broad drug-distribution re-rating.

Near term, estimate revisions can support the shares, but the article offers no independent evidence on GLP-1 gross-profit dollars, cash conversion, or contract economics; the promotional framing is therefore not a standalone catalyst. Over the next 1-3 months, focus on whether management raises operating-profit guidance and whether specialty/RxTS growth outpaces pharmaceutical distribution revenue. Over 6-18 months, payer pressure, pharmacy benefit manager reimbursement changes, GLP-1 supply normalization, or manufacturer direct-distribution initiatives could compress the service premium that investors are implicitly capitalizing.

Contrarian view: the market may be over-attributing GLP-1 sales growth to earnings power. If volumes normalize while mix shifts toward lower-margin product distribution, MCK can still deliver revenue growth but miss the operating-leverage narrative, creating downside through both estimate cuts and multiple compression. Conversely, evidence that access services and oncology attach rates are rising would justify a premium versus COR rather than a sector-level trade.

Key Decisions for Investors

• Maintain or initiate a modest long MCK / short COR pair over a 3-6 month horizon only after the next earnings release confirms specialty/RxTS operating-profit growth above core distribution growth; target 8-12% relative upside, with exit if MCK fails to raise full-year operating-profit guidance or cash conversion weakens.
• Do not chase MCK solely on the reported analyst revisions. Set an alert for disclosed GLP-1-related gross-profit contribution, inventory days, and operating cash flow; absent these data, treat the signal as watch-list quality rather than a new standalone position.
• Use CAH as the sector hedge rather than XLV: if MCK re-rates on services monetization, long MCK/short CAH isolates company-specific execution; reverse or close if CAH shows comparable specialty-services acceleration, which would undermine the differentiation thesis.
• For existing MCK longs, reduce risk ahead of any guidance event if the stock materially outperforms COR without a corresponding upward revision to FY operating-profit or free-cash-flow expectations; the primary downside is a revenue-versus-margin disappointment, not a collapse in drug demand.